Tau

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

Retrieved on: 
Monday, March 25, 2024
Plasma, Conference, Tau, Cell, Disease, CSF, Patient, Biomarker, Research, Median, Asian literature, ADAS-Cog, Tau protein, Safety, NK, Amyloid, Pharmaceutical industry

SANTA ANA, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (“NK”) cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the Tau2024 Global Conference in Washington, D.C.

Key Points: 
  • The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease in addition to previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers.
  • Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12 weeks after the final dose.
  • “The data presented today demonstrate additional beneficial effects of SNK01 for the treatment of Alzheimer’s disease,” commented Paul Y.
  • While the results were positive, the Phase 1 trial was a dose-escalation trial that only administered four total doses over 11 weeks.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on: 
Wednesday, March 27, 2024
Seniors, Nanotechnology, Research, Software, Medical Devices, Hardware, Consumer, Genetics, Professional Services, Science, Technology, Clinical Trials, Publishing, Data Analytics, Biotechnology, Health, Communications, Health Technology, National Geographic, MicroRNA, Brain, Gene, Myenteric plexus, Gene expression, NanoString Technologies, Cell, Disease, Memory, Alzheimer's disease, Tau, Risk, Hippocampus, Inflammation, Patient, RNA, News, Federal republic, Protein, Biology, Proteomics, Publication, OTC, Ecosystem, Multimedia, SMI, Ageing

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points: 
  • When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
  • (Graphic: NanoString)
    A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
  • NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.

New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Neurology, General Health, Research, Science, Biotechnology, Diagnosis, EV, Brain, Plasma, Conference, Dementia, EVS, CSF, Tau, Alzheimer's disease, Sunbird, AUC, Patient, PET, Biomarker, Traffic barrier, APEX, Cerebrospinal fluid, Protein, Neuron, Trial of the century, Aggregation, DSM-IV codes, Blood, Medical imaging

“These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.

Key Points: 
  • “These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • “This confirmed correlation between EV-bound tau in the blood and tau tangles in the brain combined with the early validation of our new tau assays is incredibly exciting.
  • The Sunbird Bio study being shared at Tau2024 evaluated the potential of EV-bound tau proteins in the blood as a method of directly detecting the tau proteins that aggregate in the brain.
  • They then used Sunbird Bio’s new proprietary tau assays to distinguish between EV-bound and unbound soluble forms of tau in plasma.

Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure

Retrieved on: 
Thursday, March 21, 2024
Science, Neurology, Cardiology, Research, Oncology, General Health, Health, Infectious Diseases, Laboratory, Partnership, Diagnosis, Tau, Corporation, FDA, Pharmaceutical industry

11,275,092—are directed specifically to our novel approach to measuring Tau protein levels in biologic samples.

Key Points: 
  • 11,275,092—are directed specifically to our novel approach to measuring Tau protein levels in biologic samples.
  • Those interested in building Alzheimer’s disease (AD) testing infrastructure should contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No.
  • With the advent of FDA approval of an AD therapy, Quanterix is focused on building the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • In conjunction with this announcement, the Company will host a conference call on March 25, 2024 at 4:00 p.m. E.T.

Alzheimer's Drug Discovery Foundation (ADDF) Statement on FDA Decision to Convene Advisory Committee for Donanemab

Retrieved on: 
Friday, March 8, 2024
Fillit, Diagnosis, Research, Peripheral, MD, Pathology, Inflammation, FDA, News, Ageing, Drug development, Entrepreneurship, Biomarker, Lilly, Tau, Medicine, Patient, Disease, Donanemab, Biology, Plasma protein binding, Pharmaceutical industry

NEW YORK , March 8, 2024 /PRNewswire/ -- Drugmaker Eli Lilly & Company today announced the FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to further review and discuss donanemab's efficacy and safety profile before making its final decision on whether to grant the drug approval. The advisory committee is scheduled to take place later this year.

Key Points: 
  • The FDA plans to hold an advisory committee to glean more information on the TRAILBLAZER-ALZ 2 trial data and safety profile.
  • The advisory committee is scheduled to take place later this year.
  • "Today's FDA decision is not a setback, but another step forward in the drug approval process, with the regulatory agency doing its due diligence before the distribution of the drug to patients," says Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF).
  • "The decision to hold an advisory committee before granting approval follows the regulatory process that was used for the other drugs in this class, including Leqembi."

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

Retrieved on: 
Monday, February 5, 2024
Research, Mental Health, Neurology, Clinical Trials, Other Health, General Health, Pharmaceutical, Health, Science, Other Science, Multimedia, Memory, Acetylcholine, Tau, Pathology, Entrepreneurship, Disease, Brain, Abstract, Dementia, Conference, Pharmaceutical industry

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.

Key Points: 
  • TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
  • If approved, HMTM will be the first oral, anti-tau therapy with a robust safety profile requiring minimal testing and treatment monitoring.
  • HMTM is primarily a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.
  • Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

Retrieved on: 
Thursday, February 1, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Massachusetts General Hospital, RNA, Hospital, Human body, Harvard University, Transcriptome, DSP, Mass meeting, SMI, Gene, Benchmarking, Tau, Dissection, Holy Grail, Weill Cornell Medicine, Alzheimer's disease, Gene expression, Medicine, Colorectal cancer, SAHA, Microscope

Under the banner, “Plex YES!”, a theme inspired by customer reactions to the high plex CosMx Human 6K Discovery Panel, NanoString team members and early access researchers will highlight the CosMx SMI’s expanded capabilities with the official product launch at the annual AGBT meeting.

Key Points: 
  • Under the banner, “Plex YES!”, a theme inspired by customer reactions to the high plex CosMx Human 6K Discovery Panel, NanoString team members and early access researchers will highlight the CosMx SMI’s expanded capabilities with the official product launch at the annual AGBT meeting.
  • With the recently announced achievement of the whole transcriptome prototype panel on the CosMx SMI, researchers can now analyze almost 19,000 genes at true single-cell and subcellular resolution.
  • "The CosMx Whole Transcriptome Panel is the ultimate tool for spatial biology; it resulted in new discoveries on my first run.
  • CosMx Human 6K Discovery Panel & CosMx Whole Transcriptome Panel:
    “NanoString Spatial Biology Roadmap: The Holy Grail of Spatial is Here,” presented by Joseph Beechem, Ph.D., Chief Scientific Officer, NanoString, Wednesday, February 7, 3:35-3:50 PM ET.

Tau Group Closes €11 Million Extension to Series-B Round to Fuel Growth and Enhance Production Capacity

Retrieved on: 
Tuesday, January 30, 2024
Tau, WM, Overalls, Financial institution, Investment, Aluminium, Ecosystem, Growth, CVC, EUR, Transport, Copper, Economic development, CDP Equity, Renewable energy

Tau has successfully closed a €11 million extension to its Series-B funding round.

Key Points: 
  • Tau has successfully closed a €11 million extension to its Series-B funding round.
  • Tau Group stands at the forefront of the energy transition, specializing in the decarbonization of energy and electrification of transport.
  • The funds raised in this extension will propel Tau Group's growth trajectory, enhancing its ability to achieve ambitious goals.
  • Tau Group is a technology company at the core of energy transition, decarbonization of energy and electrification of transport.

Tau Group Closes €11 Million Extension to Series-B Round to Fuel Growth and Enhance Production Capacity

Retrieved on: 
Tuesday, January 30, 2024
Tau, WM, Overalls, Financial institution, Investment, Aluminium, Ecosystem, Growth, CVC, EUR, Transport, Copper, Economic development, CDP Equity, Renewable energy

Tau has successfully closed a €11 million extension to its Series-B funding round.

Key Points: 
  • Tau has successfully closed a €11 million extension to its Series-B funding round.
  • Tau Group stands at the forefront of the energy transition, specializing in the decarbonization of energy and electrification of transport.
  • The funds raised in this extension will propel Tau Group's growth trajectory, enhancing its ability to achieve ambitious goals.
  • Tau Group is a technology company at the core of energy transition, decarbonization of energy and electrification of transport.

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Retrieved on: 
Monday, January 22, 2024
Roche, Tau, AC, GMP, Antibody, Genentech, Immune system, Vaccine

AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements.

Key Points: 
  • AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements.
  • AC Immune will carefully review and evaluate available data sets, including the final open label extension results from the Lauriet trial when they become available and are received in full by AC Immune, before decisions are made on potential further development and other opportunities.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune is highly focused on progressing its three active immunotherapies from its precision medicine pipeline.
  • “Regaining the global rights to crenezumab, semorinemab and the intellectual property surrounding these targets may offer alternative routes to new growth opportunities, including combination therapies.